Ozempic vs Wegovy (injectable)

This is the most important fact for anyone comparing Ozempic and Wegovy: they are the same active ingredient (semaglutide) from the same manufacturer (Novo Nordisk). The difference is the maximum dose and the FDA-approved indication.

• Ozempic: doses 0.25, 0.5, 1.0, 2.0 mg weekly. FDA-approved for type 2 diabetes and for cardiovascular risk reduction in diabetics with established CVD.
• Wegovy: doses 0.25, 0.5, 1.0, 1.7, 2.4 mg weekly. FDA-approved for chronic weight management in adults and adolescents ≥12, and for CV risk reduction in adults with obesity and established CVD.

At equivalent doses, they are pharmacologically identical. The "Ozempic for weight loss" phenomenon of 2020–2023 was off-label prescribing of a lower-dose version of the exact drug that Novo then approved for weight loss at a higher dose.

Weight loss is dose-dependent within the semaglutide curve:

• Ozempic 1.0 mg: ~6% weight loss in type 2 diabetes (SUSTAIN-7), ~8–10% in non-diabetics off-label.
• Ozempic 2.0 mg: ~10–14% weight loss off-label in non-diabetics; similar dose-response to SUSTAIN-FORTE.
• Wegovy 2.4 mg: 14.9% weight loss in STEP-1 (non-diabetics over 68 weeks).

The gap between Ozempic 2.0 and Wegovy 2.4 is partly dose, partly patient selection. For patients whose primary goal is weight loss, Wegovy's 0.4 mg additional dose plus on-label prescribing adds up to meaningfully better real-world outcomes.

Despite being the same molecule, Ozempic and Wegovy are handled very differently by insurance.

Diabetes coverage (Ozempic's lane): broad. Commercial plans have covered GLP-1s for type 2 diabetes for years. Medicare Part D covers Ozempic. State Medicaid coverage is common.

Obesity coverage (Wegovy's lane): much narrower but expanding. Commercial coverage improved significantly 2023–2026; most major plans now cover Wegovy with PA. Medicare Part D does not cover obesity-only indications but does cover Wegovy for its cardiovascular indication in some cases. State Medicaid varies widely.

Off-label Ozempic for weight loss: almost never covered. Plans run edits that match diagnosis code to indication; obesity-coded Ozempic claims get denied.

Cash paths:

• Ozempic retail cash: ~$999/month.
• Wegovy retail cash: ~$1,349/month.
• Both available at $499/month via NovoCare direct for eligible cash-pay patients.

Identical molecule means identical side effect profile at identical doses. The practical difference is dose magnitude: patients on Wegovy 2.4 mg experience somewhat more nausea, diarrhea, and vomiting than patients on Ozempic 1.0 mg, but less than patients pushing Ozempic 2.0 mg.

The boxed warning for thyroid C-cell tumors, contraindications in MTC/MEN 2, pancreatitis risk, gallbladder risk, pregnancy contraindication, and 1-week pre-op hold all apply identically.

Pick Ozempic if: you have type 2 diabetes (on-label, insurance will cooperate), or you're already on Ozempic for diabetes and losing weight as a secondary benefit.

Pick Wegovy if: weight loss is your primary goal, you don't have diabetes, and you want the higher maintenance dose plus insurance coverage aligned with your diagnosis code.

Avoid off-label Ozempic for weight loss in 2026 unless you have a specific coverage reason. It was a reasonable workaround in 2021; today Wegovy is easier, cheaper, and produces more weight loss at the 2.4 mg dose.